Hillmen P, et al. - In a phase 2 trial (CLARITY trial) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), researchers assessed how combined ibrutinib with venetoclax performed, with the intention of treatment cessation. They focused on eradication of measurable residual disease (MRD) following 12 months of combined therapy (primary end point) as well as on response by International Workshop on CLL criteria, safety, and progression-free and overall survival (secondary end points). Findings revealed good tolerability of the combination of ibrutinib plus venetoclax in patients with relapsed or refractory CLL. Some patients could stop therapy because the MRD eradication rate was high. With this combined therapy, encouraging progression-free and overall survival rates were achieved.